Elizabeth Khalilian

Elizabeth Khalilian

Auto-generated profile, based on publicly available information

Elizabeth Khalilian

HumanITcare - FOLLOWHEALTH SL, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
NPNúria Pastor
Núria Pastor
EKElizabeth Khalilian
Elizabeth Khalilian
ECElsa Caballeria
Elsa Caballeria
DMDanielle Morrison
Danielle Morrison
ULUnai Sanchez Luque
Unai Sanchez Luque
Hugo Lopez-PelayoHugo Lopez-Pelayo
Hugo Lopez-Pelayo
Background: Monitoring mental health outcomes has traditionally been based on heuristic decisions, often based on scarce, subjective evidence, making the clinical decisions made by professionals, as well as the monitoring of these diseases, subject to flaws. However, the digital phenotype, which refers to the analysis of data collected by measuring human behavior with mobile sensors and smart bracelets, is a promising tool for filling this gap in current clinical practice. Objective: The objectives of this study are to develop the digital phenotyping of patients with alcohol use disorder and anxiety symptoms using data collected from a mobile device (ie, smartphone) and a wearable sensor (ie, Fitbit) and to analyze usability and patient satisfaction with the data collection service provided by the app. Methods: We propose to conduct a study among a group of 60 participants split into two subgroups—experimental and control—of 30 participants each. The experimental group will be recruited by physicians from the Hospital Clínic de Barcelona, and the control group will be recruited on a volunteer basis through fliers and social media. All participants will go through pretraining to ensure technological capability and understanding of tasks, then each participant will download the HumanITcare app and will be given a wearable sensor (ie, Fitbit). Throughout the 4-month period, participants will be monitored on a range of factors, including sleep cycle, heart rate, movement patterns, and sociability. All data from the wearable sensors and the mobile devices will be saved and sent to the HumanITcare server. Participants will be asked to complete weekly questionnaires about anxiety, depression, and alcohol use disorder symptoms. Research assistants will ensure timely responses. The data from both sensors will then be compared to the questionnaire responses to determine how accurately the devices can predict the same symptoms. Results: The recruitment phase was completed in November 2019 and all the data were collected by the end of December 2019. Data are being processed; this process is expected to be completed by October 2020. Conclusions: This study was created and conducted as a pilot study with the Hospital Clínic de Barcelona, with the purpose of exploring the feasibility of our approach. The study is focused on patients diagnosed with anxiety and alcohol use disorder, but participants were also monitored for depressive symptoms throughout the trial, although these were not part of the initial inclusion criteria. A limitation to our study was the exclusive use of Android smartphones over iOS devices; this could result in a potential selection bias, due to the accessibility and affordability of Android phones as opposed to iOS-based phones. Another limitation might be that reviews of usability and satisfaction could be confounded by factors such as age and familiarity. An additional function that we might add in future studies is the ability for patients to manage their own data. International Registered Report Identifier (IRRID): DERR1-10.2196/16964

8 November 2019 in JMIR Preprints
Verified
Preprint
Open access
NPNúria Pastor
Núria Pastor
EKElizabeth Khalilian
Elizabeth Khalilian
ECElsa Caballeria
Elsa Caballeria
DMDanielle Morrison
Danielle Morrison
ULUnai Sanchez Luque
Unai Sanchez Luque
Hugo Lopez-PelayoHugo Lopez-Pelayo
Hugo Lopez-Pelayo
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: In the EU, approximately 165 million people suffer from mental health disorders, namely anxiety, mood disorders, and substance abuse. These mental health disorders have resulted in both direct and indirect global economic costs estimated at US $2.5 trillion in 2010, with the indirect costs (USD $ 1.7 trillion) being significantly higher than the direct costs (USD $ 0.8 trillion), contrasting the trends of other key diseases, such as cardiovascular disease and cancer [1]. Concurrently, problematic alcohol consumption is considered the causal factor of more than 200 diseases, leading to 5.1% of all global diseases and damages being attributed to alcohol abuse. In addition to the risks posed to health, the social and economic damages involved not only for individuals suffering from alcohol abuse, but for society in general, must be taken into consideration [2]. Monitoring mental health outcomes has traditionally been based on heuristic decisions often based on scarce, subjective evidence, making the clinical decisions made by professionals, as well as the monitoring of these diseases, subject to flaws [3]. However, the "digital phenotype", which refers to the analysis of data collected by measuring human behavior with mobile sensors and smart bracelets, is a promising tool for filling this gap in current clinical practice, offering objective evidence in an otherwise subjective field of diagnosis, namely through the utilization of digital biomarkers [4]. Biomarkers are physiological, pathologic, or anatomic characteristics measured objectively and used to evaluate a patient’s health in the status quo by comparing their current biomarkers to ideal, healthy biomarkers. In the wake of advancing technology, “digital biomarkers” are emerging as a new form of tracking patient’s health. Digital biomarkers are considered digital as they utilize sensors and computational tools to collect data. These measurements can be taken outside of a traditional clinical environment using sensors such as mobile device sensors and wearable sensors [5]. Numerous studies have shown that information collected from behavioral and physiological sensors can be used to improve conventional evaluations of patients with symptoms of anxiety. In addition, patients who use these platforms show higher levels of consistency with their treatment plans than those only involved in conventional practice [6]. There are various examples of the effectiveness of digital phenotype data-collection in analyzing anxiety disorders: There exist significant patterns between the time spent in certain places and depression and anxiety, although these relationships were not consistent [7]. It has been shown that sensors integrated into smart bracelets measuring conductance and skin temperature can be utilized to reach a 78.3% (148/189) accuracy in classifying students into groups of high or low stress levels. Furthermore, the sensors provided a 79% (37/47) accuracy rate for classifying students’ state of mental health [8]. Furthermore, analysis from sensors tracking GPS location and incoming and outgoing text messages and calls collected from 54 college students over a two week period indicated that levels of social anxiety can be predicted with an accuracy of up to 85% by tracking these variables [9]. Alongside digital tracking of anxiety symptoms, there also exist various applications designed to facilitate the monitoring of alcohol consumption in patients with alcohol abuse disorder [10,11,12]. Although more research is needed, these applications have been shown to be effective in increasing patients’ ability to manage their condition [10], leading to reductions in days of consumption risk [11]. In addition, these tools allow for patients’ usual professional caretaker to monitor their condition, allowing for more informed care [10]. Therefore with REMOTE study we aim to provide valuable insights and knowledge about digital biomarkers in alcohol use disorders and anxiety disorders. Objective: Because of the emerging research on digital biomarkers and in the accuracy of passive monitoring of data in patients with mental health disorders, we pose a study in a group of 60 participants split into two subgroups of 30 participants. The primary objective of this study is to analyze the digital physiological patterns of two groups of participants, one group with symptoms of anxiety disorder and alcohol abuse disorder and one healthy control group without anxiety and alcohol abuse disorder, using data collected from a mobile (smartphone) and wearable (FitBit) sensor. The data collected from the sensors trough humanITcare platform will then be compared with the symptoms validated in clinical questionnaires, which participants will take four times over the course of the study, in order to determine whether sensor data is an efficient and accurate means of presenting objective diagnoses rather than the subjective diagnosis of the status quo. The secondary objective of this study is to analyze usability and patient satisfaction with the data collection service provided by the application. Methods: DESING: This study is a case-controlled, prospective study consisting of two groups: one group of healthy control...